L-Dopa activates histaminergic neurons.
L-Dopa is the most effective treatment of early and advanced stages of Parkinson's disease (PD), but its chronic use leads to loss of efficiency and dyskinesia. This is delayed by lower dosage at early stages, made possible by additional treatment with histamine antagonists. We present here evidence that histaminergic tuberomamillary nucleus (TMN) neurons, involved in the control of wakefulness, are excited under L-Dopa (EC50 15 μM), express Dopa decarboxylase and show dopamine immunoreactivity. Dopaergic excitation was investigated with patch-clamp recordings from brain slices combined with single-cell RT-PCR analysis of dopamine receptor expression. In addition to the excitatory dopamine 1 (D1)-like receptors, TMN neurons express D2-like receptors, which are coupled through phospholipase C (PLC) to transient receptor potential canonical (TRPC) channels and the Na+/Ca2+ exchanger. D2 receptor activation enhances firing frequency, histamine release in freely moving rats (microdialysis) and wakefulness (EEG recordings). In histamine deficient mice the wake-promoting action of the D2 receptor agonist quinpirole (1 mg kg⁻¹, I.P.) is missing. Thus the histamine neurons can, subsequent to L-Dopa uptake, co-release dopamine and histamine from their widely projecting axons. Taking into consideration the high density of histaminergic fibres and the histamine H3 receptor heteromerization either with D1 or with D2 receptors in the striatum, this study predicts new avenues for PD therapy.
Department of Neurophysiology, Heinrich-Heine-University, D-40001, Dusseldorf, Germany.
Yevgenij
Y
Yanovsky
Sha
S
Li
Boris P
BP
Klyuch
Qiaoling
Q
Yao
Patrizio
P
Blandina
M Beatrice
MB
Passani
Jian-Sheng
JS
Lin
Helmut L
HL
Haas
Olga A
OA
Sergeeva
D000818:Animals; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006632:Histamine / Q000378:metabolism*; D007026:Hypothalamic Area, Lateral / Q000187:drug effects* / Q000378:metabolism*; D007980:Levodopa / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism
D007980:Levodopa; D006632:Histamine; D004298:Dopamine
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7731-6
9636219
J Comp Neurol. 1988 Jul 15;273(3):283-300
3062046
J Neurophysiol. 2008 Feb;99(2):442-59
18094105
Life Sci. 1984 Dec 3;35(23):2281-96
6390056
Brain Res Bull. 1982 Jul-Dec;9(1-6):321-53
6816390
J Neurosci. 2001 Dec 1;21(23):9273-9
11717361
Pharmacol Biochem Behav. 2008 Sep;90(3):325-30
18452981
Eur J Neurosci. 2005 Jan;21(1):290-4
15654868
Physiol Rev. 2008 Jul;88(3):1183-241
18626069
J Neurosci. 2006 Oct 11;26(41):10577-89
17035544
Neuropharmacology. 2002 May;42(6):772-81
12015203
Eur J Neurosci. 2001 Jul;14(1):125-34
11488956
Trends Pharmacol Sci. 2005 Nov;26(11):578-86
16183137
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S101-4
20082966
J Biol Chem. 2010 Jul 30;285(31):23985-93
20511229
Eur J Neurosci. 2002 Oct;16(8):1472-82
12405960
J Comp Neurol. 1987 Sep 1;263(1):1-24
2822770
Mol Pharmacol. 1985 Aug;28(2):138-45
2410769
Sleep Med Rev. 2007 Apr;11(2):113-33
17275369
Neurotox Res. 2008 May-Jun;13(3-4):231-40
18522902
Exp Neurol. 2000 May;163(1):20-30
10785440
FASEB J. 2006 Jun;20(8):1263-5
16636101
J Physiol. 2003 Aug 1;550(Pt 3):911-9
12824447
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):659-78
16741673
J Neurosci. 2002 Sep 1;22(17):7695-711
12196593
J Neurosci. 2009 Nov 18;29(46):14423-38
19923277
Neurosci Lett. 2004 Jul 8;364(3):179-84
15196671
J Neural Transm Suppl. 1986;22:19-32
2431109
J Neurosci. 2009 Apr 8;29(14):4471-83
19357273
Eur J Neurosci. 2006 Sep;24(5):1413-26
16965543
Ann Neurol. 1991 Jun;29(6):577-84
1892359
Br J Pharmacol. 2009 May;157(1):64-75
19413572
Psychopharmacology (Berl). 2007 Feb;190(2):251-63
17072589
Trends Pharmacol Sci. 2005 Jul;26(7):341-4
15936832
J Comp Neurol. 1994 Sep 1;347(1):101-14
7798375
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1964-9
11172059
J Chem Neuroanat. 1993 Sep-Oct;6(5):293-310
7506039
J Physiol. 2009 Feb 15;587(Pt 4):713-9
19218620
Neuropharmacology. 2007 Feb;52(2):626-33
17070873
J Pharmacol Exp Ther. 2011 Jan;336(1):17-23
20864502
J Physiol. 1988 May;399:633-46
3404470
Neuropharmacology. 2008 Jul;55(1):94-105
18547595
Br J Pharmacol. 1990 Jun;100(2):257-60
2165836
Biochem Pharmacol. 2007 Apr 15;73(8):1157-71
17288995
Brain. 2007 Jun;130(Pt 6):1577-85
17470494
Eur J Neurosci. 2006 Sep;24(6):1633-44
17004927
Neuropharmacology. 2001 Mar;40(3):345-51
11166327
Exp Neurol. 2008 Jul;212(1):230-3
18501350
Neurosci Lett. 2002 Mar 8;320(3):133-6
11852180
Pol J Pharmacol. 2004 Nov-Dec;56(6):659-71
15662079
Brain Res Bull. 1982 Jul-Dec;9(1-6):367-8
7172035
Neurology. 2006 Oct 10;67(7 Suppl 2):S12-7
17030735
J Neurosci. 1990 Aug;10(8):2587-600
2143777
Neuropharmacology. 2008 Aug;55(2):190-7
18547596
J Physiol. 1991 Nov;443:405-19
1688025
Prog Brain Res. 2006;153:243-52
16876579
Neurology. 1994 Jan;44(1):84-9
7904735
BMC Neurosci. 2008 Feb 24;9:26
18294400
Neurosci Lett. 1995 Aug 4;195(2):113-6
7478263
Restor Neurol Neurosci. 1998;12(4):213-221
12671291